Effects of Intravitreal Aflibercept on the Systemic Insulin-like Growth Factor-I and Vascular Endothelial Growth Factor-A in Patients with Diabetic Retinopathy and Age-Related Macular Degeneration

Table 2

Systemic VEGF-A and IGF-1 concentrations.

	AMD	PDR	NPDR	(AMD vs. DR)
VEGF-A (median/mean (pg/ml)) at B (IQR)	43/43 (30–57)	54/73 (29–138)	52/77 (31–109)	(MW)
VEGF-A (median/mean (pg/ml)) 1 week (IQR)	8/9 (8–8)	3/4 (0–7)	2/2 (1–3)	(MW)
VEGF-A (median/mean (pg/ml)) 4 weeks (IQR)	17/20 (8–25)	14/13 (9–19)	20/20 (13–24)	(MW)
	(F); (B vs. 1 week); (B vs. 4 weeks)	(F; DR over time); (B vs. 1 week); (B vs. 4 weeks)
IGF-1 (median/mean (pg/ml)) at B (IQR)	35/37 (24–51)	83/82 (48–117)	54/59 (29–88)	(MW)
IGF-1 (median/mean (pg/ml)) 1 week (IQR)	41/38 (27–45)	71/129 (45–243)	43/48 (29–66)	(MW)
IGF-1 (median/mean (pg/ml)) 4 weeks (IQR)	41/39 (28–48)	82/98 (34–181)	40/51 (34–58)	(MW)
	(F); (B vs. 1 week); (B vs. 4 weeks)	(F; DR over time); (B vs. 1 week); (B vs. 4 weeks)

AMD: age-related macular degeneration; DR: diabetic retinopathy; PDR: proliferative diabetic retinopathy; NPDR: nonproliferative diabetic retinopathy; VEGF-A: vascular endothelial growth factor-A; IGF-1: insulin-like growth factor-1; B: baseline; MW: Mann–Whitney test; F: Friedman test.